DR.TE has been strictly certified by China's CFDA, and is a German process gel-type injectable cross-linked sodium hyaluronate gel, which is usually called hyaluronic acid. DR.TE contouring aesthetics is designed for the development of Asian facial bones and tissues, and combined with the emotional and behavioral habits of Asians, the aesthetics of the program is designed for the needs of the facial contouring customers to match the Suitable hyaluronic acid facial solutions to meet the injection needs of different parts of the face of the candidates.
This product has non-displacement, non-diffusion, long-lasting and stable effect, strong anti-enzymatic, free radical decomposition ability, safe and reliable, closest to the body's own traits, reversed-phase cross-linking technology, endotoxin, cross-linking agent, protein residues 2-3 times lower than the national standard. Adverse reaction rate <1‰. Unique reverse-phase cross-linking technology minimizes inflammation-inducing substances such as proteins and endotoxins. The residual amount of cross-linking agent is less than 0.8ppm, which is 75% lower than the national standard.
DR.TE is produced under the German NMI patented process, German original HOPM fully automated production technology with less cross-linking agent in the reverse phase cross-linking, higher cross-linking degree; homogeneous gel stronger anti-enzymatic ability, the whole, stable and long-lasting. The production adopts GMP 100,000 + 10,000 grade sterile production workshop, which enhances the ductility and holding power of hyaluronic acid. The syringe adopts BD explosion-proof needle technology: 12N pushing force, time-saving, precise injection, low pain.Precautions
Not to be performed at the same time with chemical peel, laser radium or scar removal procedures, should ensure that the two types of procedures have a certain time interval. It is contraindicated in patients with a history of severe allergy and a predisposition to hypertrophic scarring after sodium hyaluronate injection. It is contraindicated in patients with abnormal clotting mechanisms or in patients who have been treated with thrombolytics, anticoagulants, or platelet coagulation inhibitors within 2 weeks. Not to be used in areas where permanent fillers have been injected, areas where non-permanent fillers have been used 6-12 months ago, and areas where facial fillers have been injected.Registration
DR.TE Registration No. 60806279 is a trademark application filed with the State Trademark Office on November 23, 2021, and the trademark was registered on May 21, 2022, successfully.
Insurance Company Coverage
DR.TE is underwritten by People's Republic of China Property and Casualty Insurance Company Limited on 06/06/2023 (PZMN202332110000000002).